Studies of infections complicating children with neoplastic disease and HIV infection focus on development of new approaches to treatment of invasive fungal infections, rapid molecular detection, and augmentation of host defenses. In developing new approaches for treatment of invasive fungal infections in immunocompromised children, we demonstrated through a translational research program that lipid formulations of amphotericin B (e.g. amphotericin B lipid complex (ABLC) and Ambisome) were more effective and less toxic than conventional antifungal therapy in experimental disseminated candidiasis and invasive pulmonary aspergillosis, providing a rational foundation for clinical trials. We then conducted phase I-II studies in immunocompromised patients, leading to FDA approval for the first lipid formulation of amphotericin B in the U. S. in children and adults. We also completed the first phase III randomized double-blind controlled trial of empirical Ambisome versus amphotericin B in persistently febrile neutropenic patients. In improving the early diagnosis and therapeutic monitoring of disseminated candidiases, we developed a rapid automated system for detection of d-arabinitol metabolite from Candida spp., in experimental disseminated candidiasis and in a multicenter clinical trial. We further demonstrated the potential utility of PCR and single strand conformational polymorphism (SSCP) for recognition of medically important opportunistic fungi. In developing new approaches for augmenting host defenses, we demonstrated that MCSF augments pulmonary host defenses against experimental invasive aspergillosis, that neutralization of IL-4 and IL-10 improves host response against aspergillosis, and that IL-15 is a potent activator of superoxide production (not through upregulation of NADPH-oxidase genes) and of antifungal activity against Candida in elutriated monocytes. We also showed that GM-CSF and interferon-g reverse corticosteroid-induced immunosuppression of antifungal neutrophil and monocyte activity against Aspergillus fumigatus. In developing approaches for enhancing mucosal defenses, we found that the mucosal peptides, cecropin, histatin, and adrenomedullin-related peptides have potent antimicrobial activity that may be translatable into novel approaches for gene therapy. In exploring the genetic molecular basis for altered host response, we also defined the molecular regulation of the phagocyte specific NADPH-oxidase, a complex enzyme system responsible for generating oxygen radicals, critical for antimicrobial and tumoricidal activities. We have characterized three of the genes, p40, p47, and p67-phox, with the intention of studying the regulation of the genes as a model for modulating host defenses determining that there are at least two highly homologous pseudogenes of p47-phox gene which have been physically mapped to within several hundred kilo bases. This explains the overrepresentation of the GT deletion seen in nearly all patients with p47-phox deficient chronic granulomatous disease. We are further defining the molecular basis for altered mannose binding protein and FcgR in contributing to immune impairment. These studies pride new approaches for more effective and safer management of severe infections in immunocompromised children.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC006830-26
Application #
2464470
Study Section
Physical Biochemistry Study Section (PB)
Project Start
Project End
Budget Start
Budget End
Support Year
26
Fiscal Year
1996
Total Cost
Indirect Cost
Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Katragkou, Aspasia; Kruhlak, Michael J; Simitsopoulou, Maria et al. (2010) Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents. J Infect Dis 201:1941-9
Roilides, Emmanuel; Simitsopoulou, Maria; Katragkou, Aspasia et al. (2009) Host immune response against Scedosporium species. Med Mycol 47:433-40
Moriyama, Brad; Henning, Stacey A; Neuhauser, Melinda M et al. (2009) Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria. Ann Pharmacother 43:1324-37
Walsh, Thomas J; Petraitis, Vidmantas; Petraitiene, Ruta et al. (2009) Diagnostic imaging of experimental invasive pulmonary aspergillosis. Med Mycol 47 Suppl 1:S138-45
Moriyama, Brad; Elinoff, Jason; Danner, Robert L et al. (2009) Accelerated metabolism of voriconazole and its partial reversal by cimetidine. Antimicrob Agents Chemother 53:1712-4
Baddley, John W; Marr, Kieren A; Andes, David R et al. (2009) Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 47:3271-5
Valdez, Jessica M; Scheinberg, Phillip; Young, Neal S et al. (2009) Infections in patients with aplastic anemia. Semin Hematol 46:269-76
Petraitis, Vidmantas; Petraitiene, Ruta; Hope, William W et al. (2009) Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob Agents Chemother 53:2382-91
Hickey, Patrick W; Sutton, Deanna A; Fothergill, Annette W et al. (2009) Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol 47:3091-7
Stergiopoulou, Theodouli; Meletiadis, Joseph; Sein, Tin et al. (2009) Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother 63:343-8

Showing the most recent 10 out of 129 publications